Table 1. Demographics, Baseline Data, and Procedure Timea.
Characteristic | Esketamine (nā=ā331) | Placebo (nā=ā329) | SMD |
---|---|---|---|
Age, median (IQR), y | 48 (36-57) | 47 (37-57) | 0.002 |
Sex | |||
Female | 195 (58.9) | 160 (48.6) | 0.21 |
Male | 136 (41.1) | 169 (51.4) | |
Height, median (IQR), m | 1.65 (1.6-1.7) | 1.67 (1.6-1.7) | 0.21 |
Weight, median (IQR), kg | 62 (55-70) | 63 (57-72) | 0.18 |
BMI, median (IQR) | 22.9 (21.1-24.9) | 23.2 (21.5-24.9) | 0.08 |
ASA physical status | |||
I | 257 (77.6) | 242 (73.6) | 0.10 |
II | 74 (22.4) | 87 (26.4) | |
Current smoker | 28 (8.5) | 35 (10.6) | 0.07 |
Hypertension | 41 (12.4) | 55 (16.7) | 0.12 |
Diabetes | 21 (6.3) | 29 (8.8) | 0.09 |
Baseline measurements | |||
SBP, median (IQR), mm Hg | 129 (118-141) | 128 (120-141) | 0.005 |
DBP, mean (SD), mm Hg | 75.4 (11.0) | 75.7 (11.2) | 0.03 |
MAP, mean (SD), mm Hg | 93.7 (11.9) | 93.9 (11.5) | 0.02 |
HR, median (IQR), beats per min | 76 (68-84) | 75 (70-82) | 0.03 |
Spo2, median (IQR), % | 100 (99-100) | 100 (99-100) | 0.02 |
Trial sites | |||
Site 1 | 220 (66.5) | 220 (66.9) | 0.01 |
Site 2 | 56 (16.9) | 54 (16.4) | |
Site 3 | 55 (16.6) | 55 (16.7) | |
Procedure time, median (IQR), min | 20 (16-25) | 18 (15-22) | 0.15 |
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); DBP, diastolic blood pressure; HR, heart rate; MAP, mean arterial pressure; SBP, systolic blood pressure; SMD, standardized mean difference; Spo2, oxygen saturation as measured by pulse oximetry.
Data are presented as number (percentage) of patients unless otherwise indicated.